Our CEO Jan Thirkettle joined Max Brennan, MSc on the BioHub podcast at the BIO International Convention 2025, for a discussion on Harness Therapeutics’ work in finely controlled protein modulation.
Jan shared insights on how we target neurodegeneration through our MISBA™ platform, unlocking disease-modifying targets.
Listen to the full discussion on the science driving our mission and Jan’s passion on building an exceptional team to deliver meaningful treatments for patients here.
#HarnessTherapeutics #TheBioHub #Biotech #Neurodegeneration